SYGNIS licenses amplification buffer to QIAGEN

Madrid/Heidelberg (ots) -

- Agreement follows a global licence agreement signed with QIAGEN in
2012.

- First non-exclusive licence agreement for a new amplification
buffer developed by Professor Salas at the CSIC laboratory.

Spanish-German biotech company SYGNIS Pharma AG (Frankfurt: LIO1;
ISIN: DE000A1RFM03, Prime Standard segment of the German Stock
Exchange) has signed a licence agreement for the distribution of a
new amplification buffer with QIAGEN, the global leader in sample and
assays technologies. This is the second agreement with QIAGEN within
9 months and the first licence agreement for the amplification buffer
technology developed by the team led by renowned Professor Margarita
Salas at the CSIC laboratory.

The recently granted licence covers a new amplification buffer, a
tool used in isothermal amplification, providing superior reaction
performance.

"With the new agreement, SYGNIS adds a global reference in the
sector in the fields of DNA amplification research and commercial
markets. This newly signed agreement shows that SYGNIS is making
progress in the commercialization of core technologies and products
designed for the DNA sequencing and amplification market. It
strengthens the network of relationships we maintain with life
science and diagnostics companies in the DNA amplification industry,"
SYGNIS' CEO Pilar de la Huerta commented.

Background

In July 2012, through X-POL, SYGNIS reached an exclusive global
licence agreement with QIAGEN for the distribution of the polymerase
QualiPhi®.

QualiIPhi® is an upgraded version of phi 29 DNA polymerase.
Compared to similar polymerase proteins on the market, the new one
exhibits enhanced properties. Being less time-consuming and having
highly superior performance characteristics, the method developed by
SYGNIS enables DNA amplification from concentrations as low as those
found in a single cell. This is extremely useful in cancer research,
among other applications.

Polymerase proteins are the main tool for amplifying long DNA
fragments and whole genomes, and are basic in research involving
analysis and modification of DNA from any species.

About SYGNIS Pharma AG: www.sygnis.de

After the merger in 2012 between X-Pol Biotech, specialising in
DNA amplification and sequencing, and SYGNIS Pharma AG, listed in the
German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN:
DE000A1RFM03), SYGNIS' new mission is to develop and distribute
technologies and products from X-Pol, which has a commercial product
in the DNA amplification segment, QualiPhi® and is currently
developing other products in the field of Next Generation Sequencing.

Disclaimer: Some statements included in this press release,
relating neither to proven financial results nor to other historical
data, should be viewed as forward-looking, i.e. not definitive. Such
statements are mainly predictions of future results, trends, plans or
goals. They should not be considered to be total guarantees since
given their very nature, they are subject to known and unknown risks,
as well as to aspects beyond human control, and can be affected by
other factors as a consequence of which the actual results, plans and
goals of SYGNIS Pharma AG may deviate greatly from the established
conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise said
statements in light of new information or future results or for any
other reason.

For further information please contact:
Pilar de la Huerta
CEO/CFO
Tel: +34-918063089
Email: pdelahuerta@sygnis.es